Diffuse Large B-cell Lymphoma Market to Show Immense Growth by 2032, Predicts DelveInsight | Leading Players to Look Out - AbbVie, Genmab, Merck, Xencor, Janssen, Roche, Biogen, Regeneron, Seagen, Takeda
September 19, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Diffuse Large B-cell Lymphoma Market to Show Immense Growth by 2032, Predicts DelveInsight | Leading Players to Look Out - AbbVie, Genmab, Merck,...
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the 62nd ASH Annual Meeting
December 07, 2020 12:01 ET
|
Autolus Therapeutics plc
AUTO3 continues to show a differentiated product profile supporting outpatient administration Conference call and webcast to be held Monday, December 7, 2020 at 4:00 pm ET / 9:00 pm GMT LONDON, Dec....
MacroGenics Presents Tebotelimab Data in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma at the 2020 ASH Annual Meeting
December 07, 2020 07:30 ET
|
MacroGenics, Inc.
53.8% ORR in relapsed/refractory DLBCL patients Preliminary duration of response of up to 168 days observed, with six of seven ongoing responses as of cut-off date ROCKVILLE, MD, Dec. 07,...
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO Virtual Congress 2020
September 18, 2020 03:05 ET
|
Autolus Therapeutics plc
- AUTO3 shows promise of a highly differentiated product profile Conference call and webcast to be held Friday, September 18, 2020 at 8:00 am EDT / 1:00 pm BST LONDON, Sept. 18, 2020 (GLOBE...
Autolus Therapeutics Announces New Data Showcasing Clinical Progress of AUTO3 in B Cell Malignancies
December 08, 2019 09:15 ET
|
Autolus Therapeutics plc
Preliminary data on AUTO3 in DLBCL demonstrate safety and feasibilty of CD19 and CD22 dual targeting CAR T 90% complete response and 100% overall survival at 12 months in CAR T naive pediatric ALL...
Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers
December 07, 2019 14:00 ET
|
Autolus Therapeutics plc
AUTO1 shows 87% MRD negative complete response in adult patients with r/r ALL, with no severe cytokine release syndrome Data presented at 61st American Society of Hematology Annual Meeting form...
Autolus Therapeutics Announces Conference Call to Review Clinical Data for Programmed T Cell Therapy Pipeline Presented at the 2019 ASH Annual Meeting
December 05, 2019 16:30 ET
|
Autolus Therapeutics plc
LONDON, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL) announced today that management will host a conference call and webcast on Monday, December 9, 2019 at 8:30 am ET /...
Autolus Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress
August 08, 2019 07:49 ET
|
Autolus Therapeutics plc
LONDON, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress
May 14, 2019 06:30 ET
|
Autolus Therapeutics plc
LONDON, May 14, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Announces Pricing of Public Offering
April 10, 2019 21:19 ET
|
Autolus Therapeutics plc
LONDON, April 10, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...